Koyfin Home > Directory > Health Care > Kindred Biosciences > EBIT

Kindred Biosciences EBIT Chart (KIN)

Kindred Biosciences annual/quarterly EBIT from 2012 to 2020. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Kindred Biosciences EBIT for the quarter ending June 06, 2020 was $-12m a -30.90% increase of 4m year over year
  • Kindred Biosciences EBIT for the last 12 months ending June 06, 2020 was $-64m a 1.54% decrease of -1m year over year
  • Kindred Biosciences Annual EBIT for 2019 was $-63m a 18.08% decrease of -11m from 2018
  • Kindred Biosciences Annual EBIT for 2018 was $-51m a 38.25% decrease of -20m from 2017
  • Kindred Biosciences Annual EBIT for 2017 was $-32m a 29.96% decrease of -9m from 2016
Other Income Statement Metrics:
  • Kindred Biosciences EBITDA for the quarter ending December 12, 2018 was $-16m a 35.48% decrease of -6m year over year
  • Kindred Biosciences Net Income for the quarter ending December 12, 2018 was $-15m a 35.43% decrease of -5m year over year
  • Kindred Biosciences Total Revenue for the quarter ending September 09, 2018 was $1m
View Chart On Koyfin

Quarterly KIN EBIT Data

06/2020$-12m
03/2020$-21m
12/2019$-15m
09/2019$-16m
06/2019$-15m
03/2019$-17m
12/2018$-16m
09/2018$-14m
06/2018$-12m
03/2018$-10m

Annual KIN EBIT Data

2019$-63m
2018$-51m
2017$-32m
2016$-22m
2015$-27m
2014$-27m
2013$-4m
2012$0m